Cancer News and Research

Latest Cancer News and Research

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD Pharmaceuticals, Inc. today announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of ponatinib, the Company's investigational BCR-ABL inhibitor.

20 Aug 2012

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Cancer may be the Harry Houdini of diseases—it often finds devious ways to escape treatment. Because cancer disables our cellular quality control mechanisms, rampant mutations that cause tumor cells to grow uncontrollably can also generate resistance to anticancer drugs. Even if 99 percent of the tumor is destroyed, that 1 percent can come roaring back. How do we knock out that 1 percent? By attacking the cancer from multiple angles, using multiple treatments and strategies.

20 Aug 2012

Enrollment complete in BDSI's pivotal pharmacokinetic study of BNX for opioid dependence

BioDelivery Sciences International, Inc. announced that enrollment and the clinical portion of the pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence has been completed.

20 Aug 2012

Protein toxic to nerve cells in AD also contributes to memory loss

The underlying causes of Alzheimer's disease are not fully understood, but a good deal of evidence points to the accumulation of β-amyloid, a protein that's toxic to nerve cells. β-amyloid is formed by the activity of several enzymes, including one called BACE1. Most Alzheimer's disease patients have elevated levels of BACE1, which in turn leads to more brain-damaging β-amyloid protein.

20 Aug 2012

Cervical cancer screening: an interview with Alastair Atkinson, CEO of DySIS Medical Ltd

Cervical Cancer is a tragic disease. First and foremost, because it is entirely preventable if the early symptoms are detected in a timely manner

20 Aug 2012

ACS National Meeting & Exposition focuses on DNA wires and their potential use in identifying diseases

In a discovery that defies the popular meaning of the word "wire," scientists have found that Mother Nature uses DNA as a wire to detect the constantly occurring genetic damage and mistakes that ― if left unrepaired ― can result in diseases like cancer and underpin the physical and mental decline of aging.

20 Aug 2012

CDC: Baby boomers should be tested for Hep C

Americans born between 1945 and 1965 are at particularly high risk for Hepatitis C and should be tested, according to new recommendations from the Centers for Disease Control and Prevention.

18 Aug 2012

UCP2 uncoupling protein occurs mainly in cells of the immune system

When uncoupling proteins are active, mitochondria produce heat instead of ATP. This may be useful under certain circumstances, such as when an animal is hibernating. But non-hibernating animals also have them. Particularly poorly understood is the uncoupling protein UCP2. Elena Pohl and colleagues at the University of Veterinary Medicine, Vienna, show that the protein occurs mainly in cells of the immune system.

18 Aug 2012

Analysis shows inconsistency in research incentives for prisoners

When members of the public participate in research studies, they are often given incentives - such as cash or gift cards for food - as compensation or reimbursement for their time and effort. Not so for Canada's prison population. A new analysis shows that there is inconsistency in how and when incentives are used for research participants under criminal justice supervision.

18 Aug 2012

Australian ruling on cigarette logo ban a 'landmark event' for global health

"The ruling this week by Australia's high court to uphold its government's right to introduce 'plain packaging' for tobacco products is a landmark event for global health," John Seffrin, CEO of the American Cancer Society, writes in this Health-e opinion piece.

18 Aug 2012

Study demonstrates how Elesclomol blocks oxidative phosphorylation in melanoma

A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.

18 Aug 2012

Computer simulations shed light on dynamic structure of major target for anti-cancer drugs

Using advanced computer simulations, University of Utah College of Pharmacy researchers have produced moving images of a protein complex that is an important target for anti-cancer drugs.

18 Aug 2012

Safety net hospitals prepare for changes from health law; Patients hesitant to challenge doctors

Safety-net hospitals – which often provide care to low-income and uninsured populations – are facing reduced federal and state support for uncompensated care under the Affordable Care Act. However, this study points out that 23 million people will remain uninsured and continue to need care from the hospitals.

18 Aug 2012

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

The U.S. Food and Drug Administration today approved the first generic version of Actos (pioglitazone hydrochloride) tablets. Along with diet and exercise, pioglitazone is used to improve blood glucose control in adults with type 2 diabetes.

18 Aug 2012

State news: Tenn. abortion clinic closes; Tex. wrestles with funding for Women's Health Program; Mich. lawmakers pass bill to cut state share of teachers' health care

A Knoxville abortion provider has closed after 38 years, citing a newly enacted Tennessee law that requires doctors to hold admitting privileges at local hospitals. The Volunteer Women's Medical Clinic in Knoxville closed Friday. In a public letter titled "End of an Era," Executive Director Deb Walsh wrote that she was unable to keep their doors open in part due to the "Life Defense Act," which requires physicians to obtain admitting privileges at area hospitals.

18 Aug 2012

Two Johns Hopkins scientists receive NCI grant for Provocative Questions project

Two Johns Hopkins scientists are among the first recipients of grants geared to answer "Provocative Questions" in cancer research, a new project funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Cynthia Sears, M.D., and Peter Searson, Ph.D., will receive more than $500,000 combined in the first of five years of funding.

17 Aug 2012

Tobacco use survey demonstrates urgent need for policy change in low and middle-income countries

An international survey of tobacco use in three billion individuals, published in the current issue of The Lancet, demonstrates an urgent need for policy change in low- and middle-income countries, according to the University at Buffalo professor who led the research.

17 Aug 2012

Two eminent cancer specialists and EORTC to be recognized at ESMO 2012 Congress

The European Society for Medical Oncology (ESMO) announced today the names of two eminent cancer specialists and one European institution that will be recognized for their contribution to the advancement of medical oncology at the ESMO 2012 Congress.

17 Aug 2012

Pyruvate kinase M2 fuels tumor growth by influencing H3 histone protein

A metabolic protein that nourishes cancer cells also activates tumor-promoting genes by loosening part of the packaging that entwines DNA to make up chromosomes, a team led by scientists at The University of Texas MD Anderson Cancer Center reports in the Aug. 16 issue of Cell.

17 Aug 2012

Study examines whether eribulin offers added benefit to women with breast cancer

Eribulin was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.

17 Aug 2012

Cancer News and Research

Latest Cancer News and Research

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Enrollment complete in BDSI's pivotal pharmacokinetic study of BNX for opioid dependence

Protein toxic to nerve cells in AD also contributes to memory loss

Cervical cancer screening: an interview with Alastair Atkinson, CEO of DySIS Medical Ltd

ACS National Meeting & Exposition focuses on DNA wires and their potential use in identifying diseases

CDC: Baby boomers should be tested for Hep C

UCP2 uncoupling protein occurs mainly in cells of the immune system

Analysis shows inconsistency in research incentives for prisoners

Australian ruling on cigarette logo ban a 'landmark event' for global health

Study demonstrates how Elesclomol blocks oxidative phosphorylation in melanoma

Computer simulations shed light on dynamic structure of major target for anti-cancer drugs

Safety net hospitals prepare for changes from health law; Patients hesitant to challenge doctors

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

State news: Tenn. abortion clinic closes; Tex. wrestles with funding for Women's Health Program; Mich. lawmakers pass bill to cut state share of teachers' health care

Two Johns Hopkins scientists receive NCI grant for Provocative Questions project

Tobacco use survey demonstrates urgent need for policy change in low and middle-income countries

Two eminent cancer specialists and EORTC to be recognized at ESMO 2012 Congress

Pyruvate kinase M2 fuels tumor growth by influencing H3 histone protein

Study examines whether eribulin offers added benefit to women with breast cancer

Industry Focus eBook - Oncology (1st Edition) eBook

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Data management challenges in scientific research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Data management challenges in scientific research

Newsletters you may be interested in